Snuppik (Drops) Instructions for Use
Marketing Authorization Holder
Stada Arzneimittel, AG (Germany)
Manufactured By
Hemomont, LLC (Montenegro)
Quality Control Release
HEMOMONT, d.o.o. (Montenegro)
Or
HEMOFARM, A.D. (Serbia)
ATC Code
R01AA05 (Oxymetazoline)
Active Substance
Oxymetazoline (Rec.INN registered by WHO)
Dosage Form
| Snuppik | Nasal drops 0.01%: bottle 5 ml with dosing device |
Dosage Form, Packaging, and Composition
Nasal drops as a clear, colorless solution.
| 1 ml | |
| Oxymetazoline hydrochloride | 0.1 mg |
Excipients: sea water, citric acid monohydrate, sodium citrate dihydrate, glycerol 85%, purified water.
5 ml – polymer bottles (1) with a pump dosing device – cardboard packs.
Clinical-Pharmacological Group
Vasoconstrictor drug for topical use in ENT practice
Pharmacotherapeutic Group
Drugs for the treatment of nasal diseases; decongestants and other drugs for topical use; sympathomimetics
Pharmacological Action
Adrenomimetic agent for topical use. It has a vasoconstrictive effect. When applied intranasally, it reduces the swelling of the mucous membrane of the upper respiratory tract.
Pharmacokinetics
When applied intranasally, T1/2 is 35 hours.
Indications
Difficulty in nasal breathing during colds, sinus inflammation, eustachitis, hay fever, allergic rhinitis.
To eliminate edema before diagnostic manipulations in the nasal passages.
ICD codes
| ICD-10 code | Indication |
| H68 | Inflammation and obstruction of Eustachian tube |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J30.1 | Allergic rhinitis due to pollen |
| J30.3 | Other allergic rhinitis (perennial allergic rhinitis) |
| J31.0 | Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis) |
| J32 | Chronic sinusitis |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| AB10.Z | Diseases of the auditory [eustachian] tube, unspecified |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA08.00 | Allergic rhinitis due to pollen |
| CA08.03 | Other allergic rhinitis |
| CA09.0 | Chronic rhinitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer intranasally only. Prior to use, clear the nasal passages of mucus.
For adults and children over 6 years: instill 1-2 drops into each nostril.
For children aged 2 to 6 years: instill 1 drop into each nostril.
Apply the solution 2-3 times per day as needed for nasal congestion.
The maximum duration of continuous use is 3 to 5 days. Do not exceed this duration.
Avoid using the product for more than 7 days in any circumstance without medical supervision.
To prevent contamination, do not touch the dropper tip to any surface, including the nasal passages.
If symptoms persist beyond the recommended treatment period, discontinue use and consult a physician.
Adverse Reactions
Local reactions possibly – burning, dryness of the nasal mucosa, sneezing; rarely – after the effect of the application wears off, the development of a strong feeling of nasal congestion (reactive hyperemia).
Systemic reactions multiple overdoses with topical application can lead to tachycardia and increased blood pressure; very rarely – anxiety, insomnia, fatigue, headaches, nausea.
Contraindications
Atrophic rhinitis, angle-closure glaucoma, hypersensitivity to oxymetazoline.
With caution
Use of MAO inhibitors and the period up to 10 days after their intake; use of drugs that promote an increase in blood pressure and the period up to 10 days after their intake; increased intraocular pressure; severe forms of cardiovascular diseases (arterial hypertension, coronary artery disease), thyrotoxicosis, diabetes mellitus, pregnancy, period of breastfeeding.
Use in Pregnancy and Lactation
Use with caution during pregnancy and lactation (breastfeeding).
Pediatric Use
Used in children according to indications in appropriate dosage forms.
Geriatric Use
Use with caution in elderly patients to avoid exacerbation of chronic diseases.
Special Precautions
Avoid prolonged use and overdose, especially in children.
Effect on the ability to drive vehicles and operate machinery
When used in doses exceeding the recommended ones, a general effect on the cardiovascular system and central nervous system cannot be excluded. In such cases, a decrease in the ability to drive vehicles and engage in other potentially hazardous activities is possible.
Drug Interactions
With simultaneous use of MAO inhibitors and tricyclic antidepressants, an increase in blood pressure is possible.
Oxymetazoline slows down the absorption of local anesthetics and prolongs their action.
Concomitant use of other vasoconstrictor drugs increases the risk of side effects.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer